Patients in the SPINRAZA arm had earlier onset of SMA, more respiratory issues, and more difficulties swallowing or feeding at baseline.
Individual results may vary based on several factors, including severity of disease, initiation of treatment, and duration of therapy.
3. Biogen. A study for participants with spinal muscular atrophy (SMA) who previously participated in nusinersen (ISIS 396443) investigational studies (SHINE). https://clinicaltrials.gov/ct2/show/study/NCT02594124?term=NCT02594124&rank=1. NLM identifier: NCT02594124. Accessed April 25, 2019.
4. Data on file. Biogen, Cambridge, MA.